NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Medivir AB (publ) (ST: MVIR-B)

 
MVIR-B Technical Analysis
5
As on 9th Jun 2023 MVIR-B STOCK Price closed @ 7.48 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 8.13 & Strong Sell for SHORT-TERM with Stoploss of 8.86 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

MVIR-BSTOCK Price

Open 7.00 Change Price %
High 7.50 1 Day 0.48 6.86
Low 7.00 1 Week -0.10 -1.32
Close 7.48 1 Month -0.24 -3.11
Volume 35823 1 Year -2.60 -25.79
52 Week High 11.20 | 52 Week Low 7.10
 
ST Sweden Most Active Stocks
QUIA 0.02 0.00%
QLIFE 0.04 0.00%
SBB-B 5.38 3.07%
STRLNG 0.12 33.33%
LUNE 21.97 6.65%
SAS 0.36 5.88%
URBIT 0.02 0.00%
IDOGEN 0.15 -31.82%
STAR-B 0.89 -1.11%
TELIA 24.60 0.41%
 
ST Sweden Top Gainers Stocks
S2M 0.52 100.00%
NETM-B 1.35 42.11%
STRLNG 0.12 33.33%
IVACC 7.26 32.97%
SPRINT 0.63 16.67%
TH1NG 1.61 16.67%
ATIC 5.14 15.77%
ATIC 5.14 15.77%
CIRCHE 3.69 15.67%
AXIC-A 8.16 15.25%
 
ST Sweden Top Losers Stocks
IDOGEN 0.15 -31.82%
IMMU 0.72 -27.27%
ALLR 1.55 -26.54%
MIDW-A 24.80 -22.98%
KILI 0.76 -16.48%
FRACTL 36.80 -14.02%
DIVIO-B 0.13 -13.33%
ZZ-B 41.50 -12.08%
LIPI 1.49 -11.83%
BACTI-B 72.70 -10.69%
 
 
MVIR-B
Daily Charts
MVIR-B
Intraday Charts
Whats New @
Bazaartrend
MVIR-B
Free Analysis
 
MVIR-B Important Levels Intraday
RESISTANCE8.44
RESISTANCE8.13
RESISTANCE7.94
RESISTANCE7.75
SUPPORT7.21
SUPPORT7.02
SUPPORT6.83
SUPPORT6.52
 
MVIR-B Forecast May 2024
4th UP Forecast11.24
3rd UP Forecast10.03
2nd UP Forecast9.29
1st UP Forecast8.54
1st DOWN Forecast6.42
2nd DOWN Forecast5.67
3rd DOWN Forecast4.93
4th DOWN Forecast3.72
 
MVIR-B Weekly Forecast
4th UP Forecast12.16
3rd UP Forecast10.66
2nd UP Forecast9.73
1st UP Forecast8.80
1st DOWN Forecast6.16
2nd DOWN Forecast5.23
3rd DOWN Forecast4.30
4th DOWN Forecast2.80
 
MVIR-B Forecast2024
4th UP Forecast16.96
3rd UP Forecast13.92
2nd UP Forecast12.04
1st UP Forecast10.16
1st DOWN Forecast4.8
2nd DOWN Forecast2.92
3rd DOWN Forecast1.04
4th DOWN Forecast-2
 
 
MVIR-B Other Details
Segment EQ
Market Capital 533393504.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
MVIR-B Address
MVIR-B
 
MVIR-B Latest News
 
Your Comments and Response on Medivir AB (publ)
 
MVIR-B Business Profile
Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name; and simeprevir. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; and MIV-711, which is in phase II clinical trial for treating osteoarthritis. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. The company has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden. Address: Lunastigen 7, Huddinge, Sweden, 141 22
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service